EpiVax

epivax.com

Epi Vax leads the industry in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. Utilizing proprietary methods for T cell epitope identification and characterization, they employ a wide range of validated in silico and in vitro techniques. This comprehensive approach provides accurate and thorough insights into candidate immunogenicity, ensuring the effectiveness and safety of their clients’ products. With over 12 million sequences analyzed and serving 17 of the top 20 pharmaceutical companies, Epi Vax has established a strong market position and significant traction in the industry.